Faeth Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $700.00K, a 600.00% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $400.00K, a 33.33% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $500.00K, a 16.67% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $100.00K, a 85.71% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $1.30M, a 60.61% decline from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $3.30M, a 25.00% decline from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $4.40M, a 46.34% decline from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $8.20M, a 192.86% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.10M 10-Q · filed 2026-08-04 | $1.60M derived: sum of 3 quarters · filed 2026-08-04 | $1.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-15 | $900.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.00M derived: sum of 3 quarters · filed 2026-05-15 | $1.10M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $600.00K derived: sum of 2 quarters · filed 2026-03-30 | $700.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.30M 10-K · filed 2026-03-30 |
| 2025-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $200.00K derived: sum of 2 quarters · filed 2026-08-04 | $800.00K 10-Q · filed 2025-11-14 | $1.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $700.00K 10-Q · filed 2026-08-04 | $1.30M derived: sum of 3 quarters · filed 2026-08-04 | $2.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-15 | $1.20M derived: sum of 2 quarters · filed 2026-05-15 | $1.90M derived: sum of 3 quarters · filed 2026-05-15 | $2.70M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.30M derived: sum of 2 quarters · filed 2026-03-30 | $2.10M derived: sum of 3 quarters · filed 2026-03-30 | $3.30M 10-K · filed 2026-03-30 |
| 2024-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.50M derived: sum of 2 quarters · filed 2025-11-14 | $2.70M 10-Q · filed 2025-11-14 | $3.60M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.00M 10-Q · filed 2025-08-05 | $2.90M derived: sum of 3 quarters · filed 2025-08-05 | $3.90M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-06 | $2.10M derived: sum of 2 quarters · filed 2025-05-06 | $3.10M derived: sum of 3 quarters · filed 2025-05-06 | $4.20M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.90M derived: sum of 2 quarters · filed 2025-03-28 | $3.00M derived: sum of 3 quarters · filed 2025-03-28 | $4.40M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.10M derived: sum of 2 quarters · filed 2024-11-14 | $3.50M 10-Q · filed 2024-11-14 | $4.80M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.50M 10-Q · filed 2024-08-06 | $3.80M derived: sum of 3 quarters · filed 2024-08-06 | $5.00M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-09 | $2.70M derived: sum of 2 quarters · filed 2024-05-09 | $3.90M derived: sum of 3 quarters · filed 2024-05-09 | $5.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.50M derived: sum of 2 quarters · filed 2024-02-29 | $4.10M derived: sum of 3 quarters · filed 2024-02-29 | $8.20M 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.80M derived: sum of 2 quarters · filed 2023-11-07 | $6.90M 10-Q · filed 2023-11-07 | $7.20M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.70M 10-Q · filed 2023-08-03 | $6.00M derived: sum of 3 quarters · filed 2023-08-03 | $6.80M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $4.10M 10-Q · filed 2023-05-09 | $4.40M derived: sum of 2 quarters · filed 2023-05-09 | $5.20M derived: sum of 3 quarters · filed 2023-05-09 | $5.80M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.10M derived: sum of 2 quarters · filed 2023-03-29 | $1.70M derived: sum of 3 quarters · filed 2023-03-29 | $2.80M 10-K · filed 2023-03-29 |
| 2021-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.40M derived: sum of 2 quarters · filed 2021-11-10 | $2.50M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.70M 10-Q · filed 2021-08-11 | ||
| 2021-03-31 | $1.10M 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $1.10M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |